Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
Industry
PHARMACEUTICAL PREPARATIONS
Address
221 CRESCENT ST.
WALTHAM, MA 02453
Phone: (781) 312-3013